Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China

Author:

Zhang Yiran,Zhang Meng,Jiang Yifei,Li Xiulian,He Yanli,Zeng Pengjiao,Guo Zhihua,Chang Yajing,Luo Heng,Liu Yong,Hao Cui,Wang Hua,Zhang Guoqing,Zhang LijuanORCID

Funder

National Natural Science Foundation of China

Key technology fund of Shandong Province

Taishan Scholar Fellowship of Shandong Province in China

Postdoctoral application research project in Qingdao, China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Reference99 articles.

1. Bai R (2010) Radiation and chemotherapy combined with lentinan to treat with non-small cell lung cancer with brain metastasis. Hebei Med J 32:2046–2047

2. Banin Hirata BK, Oda JMM, Losi Guembarovski R et al (2014) Molecular markers for breast cancer: prediction on tumor behavior. Dis Mark 2014:1–12

3. Bao L, Wang Y, Ma R et al (2015) Apoptosis-inducing effects of lentinan on the proliferation of human bladder cancer T24 cells. Pak J Pharm Sci 28:1595–1600

4. Barrett SV (2010) Breast cancer. J R Coll Physicians Edinb 40:335–339

5. Bekkering S, Blok BA, Joosten LA et al (2016) In vitro experimental model of trained innate immunity in human primary monocytes. Clin Vaccine Immunol 23:926–933

Cited by 76 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3